---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000049"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:28:31.466449+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou initiates dose expansion of CB-010 ANTLER trial in second-line LBCL patients

## Summary
- CB-010 is first allogeneic CAR-T evaluated in second-line LBCL, per company.
- Dose expansion will test 80x10^6 and 120x10^6 CAR-T cells in ~30 patients.
- In dose escalation, no DLTs at dose level 3; at dose level 1, 6/6 complete response, 3/6 at 6 months, 2/6 at 12 months.
- Company expects safety/efficacy update in H2 2023 with data from at least 15 dose-escalation patients.

## SEC filing metadata
- accession: 0001619856-23-000049
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000049/0001619856-23-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000049/crbu-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000049
- JSON: https://secwatch.observer/filing/0001619856-23-000049.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.